Skip to Content

Sustiva (efavirenz) Disease Interactions

There are 5 disease interactions with Sustiva (efavirenz):

Moderate

Efavirenz (Includes Sustiva) ↔ Cholesterol

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperlipidemia

Increases in total cholesterol and triglycerides have resulted during treatment with efavirenz. Lipid levels monitoring should be performed before starting treatment and at periodic intervals during therapy.

References

  1. "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals, Wilmington, DE.
Moderate

Efavirenz (Includes Sustiva) ↔ Liver Disease

Moderate Potential Hazard, High plausibility

Applies to: Liver Disease, Infectious Hepatitis

Efavirenz is primarily metabolized by the liver. Patients with liver disease may be at greater risk for adverse effects from efavirenz due to decreased drug clearance. Therapy with efavirenz should be administered cautiously in patients with liver disease. In addition, elevations in serum transaminases to greater than five times the upper limit of normal as well as acute liver failure requiring transplantation have occurred during therapy with efavirenz, most often in patients with a prior history of Hepatitis B and/or C. Monitoring of liver function tests is recommended in these patients.

References

  1. "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals, Wilmington, DE.
Moderate

Efavirenz (Includes Sustiva) ↔ Mental Symptoms

Moderate Potential Hazard, Low plausibility

Applies to: Psychosis, History - Psychiatric Disorder, Drug Abuse/Dependence, Alcoholism, Depression

During clinical trials, there have been infrequent reports of delusions and inappropriate behavior associated with the use of efavirenz, predominantly in patients with a history of mental illness or substance abuse. Severe acute depression, including suicide attempts and suicidal ideation, has also been reported but was not limited to efavirenz treated patients. Therapy with efavirenz should be administered cautiously in patients with a current or past history of psychiatric illness, emotional instability, or substance abuse. If symptoms develop or worsen during treatment, discontinuation of efavirenz may be necessary.

References

  1. "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals, Wilmington, DE.
Moderate

Efavirenz (Includes Sustiva) ↔ Seizures

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures

Convulsions have been observed in adult and pediatric patients receiving efavirenz, generally in the presence of known medical history of seizures. Caution should be taken with any patient with a history of seizures. Anticonvulsant medication such as phenytoin and phenobarbital may require periodic monitoring of plasma levels.

Moderate

Rilpivirine (Includes Sustiva) ↔ Qt Prolongation

Moderate Potential Hazard, Moderate plausibility

Applies to: Long QT Syndrome

Supratherapeutic doses of rilpivirine have shown to prolong the QTc interval of the electrocardiogram in healthy subjects. Rilpivirine should be used with caution in patients with a risk of arrhythmias and Torsade de Pointes or taking other medications with similar effects.

Sustiva (efavirenz) drug Interactions

There are 937 drug interactions with Sustiva (efavirenz)

Sustiva (efavirenz) alcohol/food Interactions

There are 2 alcohol/food interactions with Sustiva (efavirenz)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide